Cargando…
End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230436/ https://www.ncbi.nlm.nih.gov/pubmed/36546451 http://dx.doi.org/10.3324/haematol.2022.282115 |
| _version_ | 1785051527410352128 |
|---|---|
| author | Chohan, Karan L. Young, Jason R. Lester, Scott Moustafa, Muhamad Alhaj Rosenthal, Allison Tun, Han W. Hoppe, Bradford S. Johnston, Patrick B. Micallef, Ivana N. Habermann, Thomas M. Ansell, Stephen M. |
| author_facet | Chohan, Karan L. Young, Jason R. Lester, Scott Moustafa, Muhamad Alhaj Rosenthal, Allison Tun, Han W. Hoppe, Bradford S. Johnston, Patrick B. Micallef, Ivana N. Habermann, Thomas M. Ansell, Stephen M. |
| author_sort | Chohan, Karan L. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10230436 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102304362023-06-01 End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET Chohan, Karan L. Young, Jason R. Lester, Scott Moustafa, Muhamad Alhaj Rosenthal, Allison Tun, Han W. Hoppe, Bradford S. Johnston, Patrick B. Micallef, Ivana N. Habermann, Thomas M. Ansell, Stephen M. Haematologica Letter to the Editor Fondazione Ferrata Storti 2022-12-22 /pmc/articles/PMC10230436/ /pubmed/36546451 http://dx.doi.org/10.3324/haematol.2022.282115 Text en Copyright© 2023 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letter to the Editor Chohan, Karan L. Young, Jason R. Lester, Scott Moustafa, Muhamad Alhaj Rosenthal, Allison Tun, Han W. Hoppe, Bradford S. Johnston, Patrick B. Micallef, Ivana N. Habermann, Thomas M. Ansell, Stephen M. End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET |
| title | End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET |
| title_full | End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET |
| title_fullStr | End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET |
| title_full_unstemmed | End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET |
| title_short | End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET |
| title_sort | end-of-treatment pet in early-stage hodgkin lymphoma: valuable in addition to interim pet |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230436/ https://www.ncbi.nlm.nih.gov/pubmed/36546451 http://dx.doi.org/10.3324/haematol.2022.282115 |
| work_keys_str_mv | AT chohankaranl endoftreatmentpetinearlystagehodgkinlymphomavaluableinadditiontointerimpet AT youngjasonr endoftreatmentpetinearlystagehodgkinlymphomavaluableinadditiontointerimpet AT lesterscott endoftreatmentpetinearlystagehodgkinlymphomavaluableinadditiontointerimpet AT moustafamuhamadalhaj endoftreatmentpetinearlystagehodgkinlymphomavaluableinadditiontointerimpet AT rosenthalallison endoftreatmentpetinearlystagehodgkinlymphomavaluableinadditiontointerimpet AT tunhanw endoftreatmentpetinearlystagehodgkinlymphomavaluableinadditiontointerimpet AT hoppebradfords endoftreatmentpetinearlystagehodgkinlymphomavaluableinadditiontointerimpet AT johnstonpatrickb endoftreatmentpetinearlystagehodgkinlymphomavaluableinadditiontointerimpet AT micallefivanan endoftreatmentpetinearlystagehodgkinlymphomavaluableinadditiontointerimpet AT habermannthomasm endoftreatmentpetinearlystagehodgkinlymphomavaluableinadditiontointerimpet AT ansellstephenm endoftreatmentpetinearlystagehodgkinlymphomavaluableinadditiontointerimpet |